Navidea Biopharma

Navidea Biopharmaceuticals, Inc. engages in the development and commercialization of precision immunodiagnostic agents and immunotherapeutic. It operates through the following segments: Diagnostics, Therapeutics, and Corporate. The company was founded in 1983 and is headquartered in Dublin, OH.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Navidea Biopharmaceuticals, Inc. (NAVB) CEO Jed Latkin on Q4 2020 Results - Earnings Call Transcript

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced its financial results for the fourth quarter and full year for the period ended December 31, 2020. “We are very excited about the progress we have made, completing all the patients in the Phase 2B NAV3-31 trial and submitting our briefing book to the FDA were milestone

Navidea Biopharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced it will host a conference call and webcast on Wednesday, March 24, 2021 at 5:00 p.m. (EDT) to discuss financial results and corporate developments for the fourth quarter ended December 31, 2020. Jed Latkin, Chief Executive Officer, Dr. Michael Rosol, Chief Medical Offi

Navidea Biopharmaceuticals to Host Fourth Quarter 2020 Earnings Conference Call and Corporate Update

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, announces that management will present a company overview and hold virtual meetings with investors at the H.C. Wainwright Global Life Sciences Virtual Conference being held March 9-10, 2021. The Navidea presentation can be accessed by registering for the H.C. Wainwright Global Life Sc

Navidea Biopharmaceuticals to Present at the H.C. Wainwright Global Life Sciences Virtual Conference

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, is pleased to announce that it has executed an agreement with the Company's largest shareholder, John K. Scott, Jr., to purchase $5 million of newly-designated Series E Redeemable Convertible Preferred Stock. Over the next 18 months, the Series E Preferred can be converted into approx

Navidea Biopharmaceuticals Announces $5 Million Private Placement with Existing Investor

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, is pleased to announce that the Company has submitted its formal Type B Meeting Request to the FDA. The FDA has granted the Type B meeting and has requested submission of the Briefing Book. The FDA will now review the Company's formal briefing documents containing results from the NAV

Navidea Biopharmaceuticals Announces Submission of Formal Type B Meeting Request with FDA and Launch of NAV3-32 Phase 2B Trial in Rheumatoid Arthritis

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that the company will be presenting at the 2021 ICR Conference on Thursday, January 14, 2021 at 2:30 p.m. Eastern Standard Time. The Company will be represented at the conference by Jed Latkin, Chief Executive Officer, and Joel Kaufman, Chief Business Officer. A live v

Navidea Biopharmaceuticals to Present at the 2021 ICR Conference On January 14, 2021

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the appointment Malcolm G. Witter to its Board of Directors. Mr. Witter brings decades of financial and corporate governance experience to the board. He currently serves as a corporate development leader for USI Insurance Services (“USI”) and is responsible for acquiri

Navidea Biopharmaceuticals Strengthens Board of Directors with the Appointment of Malcolm Witter

Is Navidea Biopharmaceuticals Inc (NYSE:NAVB) a good place to invest some of your money right now? We can gain invaluable insight to help us answer that question by studying the investment trends of top investors, who employ world-class Ivy League graduates, who are given immense resources and industry contacts to put their financial expertise to work. The top picks of these firms have historically outperformed the market when we account for known risk factors, making them very valuable investment ideas.

Is Navidea Biopharmaceuticals Inc (NAVB) A Good Stock To Buy?

Navidea Biopharmaceuticals, Inc. (NAVB) CEO Jed Latkin on Q3 2020 Results - Earnings Call Transcript

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced its financial results for the third quarter and year-to-date for the period ended September 30, 2020. “Navidea continues to build on its clinical momentum and this quarter fully shows our ability to execute during a very trying time globally,” said Mr. Jed A. Latkin, C

Navidea Biopharmaceuticals Reports Third Quarter and Year-to-Date 2020 Financial Results

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, is pleased to announce positive results from analysis of subjects who have completed Arm 3 of the Company's ongoing NAV3-31 Phase 2B study. These data further corroborate Navidea's hypotheses that Tc99m tilmanocept imaging can provide robust, quantitative imaging in patients with acti

Navidea Biopharmaceuticals Announces Positive Results Encompassing Additional Patients From Its Ongoing Phase 2B Study in Rheumatoid Arthritis

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced it will host a conference call and webcast on Thursday, November 12, 2020 at 5:00 p.m. (EST) to discuss financial results and corporate developments for the third quarter ended September 30, 2020. Jed Latkin, Chief Executive Officer, Dr. Michael Rosol, Chief Medical Of

Navidea Biopharmaceuticals to Host Third Quarter 2020 Earnings Conference Call and Corporate Update

Navidea (NAVB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Navidea Biopharma (NAVB) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that members of management will participate in the Virtual Investor KOL Roundtable on Wednesday, October 28, 2020 at 4:00 PM ET. Participating in the KOL Roundtable discussion will be Jed Latkin, Navidea's Chief Executive Officer and Michael Rosol, Ph.D., Chief Medical

Navidea Biopharmaceuticals to Present at the Virtual Investor KOL Roundtable

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that the American College of Rheumatology (“ACR”) has accepted the results from the Company’s second interim analysis of its ongoing NAV3-31 Phase 2b clinical study for presentation at the ACR Annual Meeting (“ACR Convergence 2020”) under the title, “Tc99m Tilmanocept

Navidea Biopharmaceuticals Announces Acceptance of Abstract for Presentation at the American College of Rheumatology Annual Meeting

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that members of Navidea’s executive leadership team and Board of Directors will ring The Opening Bell® at the New York Stock Exchange (NYSE) on Tuesday, September 29, 2020. “This is a very proud day for the Navidea team as we approach the launch of the next phase of ou

Navidea Biopharmaceuticals to Ring Opening Bell at the New York Stock Exchange

Navidea Biopharmaceuticals: Too Many Risks Involved

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that Mr.

Navidea Biopharmaceuticals to Present at H.C. Wainwright 22nd Annual Global Investment Conference

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, is pleased to announce that on September 2, 2020 the Supreme Court of the State of New York, New York County (the “Court”) has dismissed with prejudice Platinum-Montaur Life Sciences LLC’s (“Platinum-Montaur”) law suit against the Company.

Navidea Biopharmaceuticals Wins Dismissal of Platinum Loan Litigation

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American:NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that Mr.

Navidea Biopharmaceuticals to Present at The LD 500 Virtual Investor Conference

Navidea Biopharmaceuticals, Inc. (NAVB) CEO Jed Latkin on Q2 2020 Results - Earnings Call Transcript

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American:NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced its financial results for the second quarter and year-to-date for the period ended June 30, 2020.

Navidea Biopharmaceuticals Reports Second Quarter and Year-to-Date 2020 Financial Results

Investors need to pay close attention to Navidea Biopharmaceuticals (NAVB) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in Navidea Biopharmaceuticals (NAVB) Stock?

ArcBest

ElectroCore Inc

Fluent Inc

GrubHub

Retail sales surging 18% in May fared well with the markets this morning, but with growing concerns over a Coronavirus resurgence, it's clear that volatility is just around the corner. We've utilized our AI to determine which stocks are overextended and worth taking a short position.

News for Navidea Biopharma Stock (NAVB)